SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. The fireside chat session is scheduled for Wednesday, December 3, in New York, N ...

Financial Position - The company has an accumulated deficit of $246.8 million as of September 30, 2025, and expects to continue incurring losses for the foreseeable future [98]. - As of September 30, 2025, the company had cash, cash equivalents, and short-term investments of $117.6 million, expected to fund operations into the first half of 2028 [99][100]. - The company reported an accumulated deficit of $246.8 million as of September 30, 2025, and anticipates continued significant operating losses in the foreseeable future [132]. - The company has no committed sources of capital and plans to finance future cash needs primarily through equity offerings and debt financings [134]. Revenue Generation - The company has not generated any revenue to date and does not expect to do so until regulatory approval for its ecDTx is obtained [101]. - The company expects to incur significant commercialization expenses if regulatory approval for any ecDTx is obtained, impacting future financial performance [132]. Fundraising and Cash Flow - The company raised a total of $353.8 million to fund operations, including $100.0 million from its IPO in April 2024 [99]. - The company entered into an Open Market Sale Agreement in April 2025, allowing for potential future sales of common stock [130]. - Net cash used in operating activities was $36.6 million for the nine months ended September 30, 2025, a decrease from $45.3 million in the same period of 2024, primarily due to reduced third-party spending [136]. - Financing activities provided net cash of $0.1 million during the nine months ended September 30, 2025, significantly lower than $89.7 million in the same period of 2024, primarily due to IPO proceeds [139]. Operating Expenses - Research and development (R&D) expenses decreased to $10.7 million for the three months ended September 30, 2025, down from $14.1 million in 2024, a reduction of $3.4 million [121]. - General and administrative (G&A) expenses were $4.5 million for the three months ended September 30, 2025, compared to $4.6 million in 2024, reflecting a decrease of $0.2 million [122]. - Total operating expenses for the three months ended September 30, 2025, were $15.1 million, down from $18.7 million in 2024, a decrease of $3.6 million [120]. - For the nine months ended September 30, 2025, R&D expenses totaled $35.0 million, down from $42.0 million in 2024, a decrease of $6.9 million [126]. - G&A expenses for the nine months ended September 30, 2025, increased to $14.5 million from $13.0 million in 2024, an increase of $1.5 million [127]. - Total operating expenses for the nine months ended September 30, 2025, were $49.6 million, down from $55.0 million in 2024, a decrease of $5.4 million [125]. - Other income, net for the three months ended September 30, 2025, was $1.3 million, down from $2.2 million in 2024, a decrease of $0.9 million [123]. Clinical Trials and Development - The company opened the BBI-355/BBI-825 combination arm of the POTENTIATE trial for enrollment in Q3 2025, with initial proof-of-concept data expected within the existing cash runway timeline [93]. - The company plans to submit an IND for BBI-940 in the first half of 2026 and anticipates delivering initial proof-of-concept clinical data within the existing cash runway timeline [94]. - The company has developed an ecDNA diagnostic called ECHO to detect ecDNA in patient tumor samples, currently used in the POTENTIATE trial [95]. - The company discontinued the monotherapy arm and combination arms of BBI-355 with third-party therapies in the POTENTIATE trial based on initial data, focusing on BBI-355 in combination with BBI-825 [96]. - The company has incurred substantial costs related to clinical trials, preclinical studies, and research and development activities, with cash flow fluctuations expected based on these activities [136]. Risks and Uncertainties - The company faces significant risks from macroeconomic and regulatory uncertainties that could adversely affect its operations and ability to raise capital [105][106]. - The company remains classified as an emerging growth company, allowing it to delay compliance with certain accounting standards until it meets specific revenue or market value thresholds [145]. Lease Obligations - Future minimum lease payment obligations under a non-cancellable lease agreement total $71.6 million as of September 30, 2025, with base rent payments commencing in July 2025 [140].

Financial Performance - Cash, cash equivalents, and short-term investments totaled $117.6 million as of September 30, 2025, down from $152.1 million at the end of 2024[14] - Net loss for Q3 2025 was $13.9 million, an improvement from a net loss of $16.5 million in Q3 2024[9] - The accumulated deficit increased to $246.8 million as of September 30, 2025, compared to $201.5 million at the end of 2024[14] - Total operating expenses for Q3 2025 were $15.1 million, down from $18.7 million in Q3 2024[13] Research and Development - Research and Development (R&D) expenses were $10.7 million for Q3 2025, a decrease of 24% compared to $14.1 million for the same period in 2024[9] - The company expects to submit an investigational new drug (IND) application for BBI-940 and initiate a first-in-human Phase 1 clinical trial in the first half of 2026[5] - Enrollment is ongoing in the BBI-355/BBI-825 combination arm of the POTENTIATE trial, with initial proof-of-concept clinical data expected within the existing cash runway timeline[3] - The company is developing BBI-940, a potentially first-in-class, orally bioavailable, selective Kinesin degrader targeting ecDNA segregation and inheritance[4] General and Administrative Expenses - General and Administrative (G&A) expenses were $4.5 million for Q3 2025, slightly down from $4.6 million in Q3 2024[9] Cash Position - The company has $118 million in cash to support operations into the first half of 2028[1]

Core Insights - Boundless Bio is advancing its pipeline focused on extrachromosomal DNA (ecDNA) to develop innovative therapies for oncogene-amplified cancers, with ongoing enrollment in the BBI-355/BBI-825 combination arm of the POTENTIATE trial and plans to initiate a first-in-human clinical trial for BBI-940 in the first half of 2026 [2][3][5] Financial Highlights - As of September 30, 2025, the company reported cash, cash equivalents, and short-term investments totaling $117.6 million, which is expected to support operations into the first half of 2028 [7][10] - Research and Development (R&D) expenses for Q3 2025 were $10.7 million, a decrease from $14.1 million in Q3 2024, while General and Administrative (G&A) expenses were $4.5 million, slightly down from $4.6 million in the same period [7][10] - The net loss for Q3 2025 was $13.9 million, compared to a net loss of $16.5 million for Q3 2024, indicating an improvement in financial performance [7][10] Research and Development Updates - The POTENTIATE clinical trial is actively enrolling patients for the combination of BBI-355 and BBI-825, with initial proof-of-concept clinical data expected within the existing cash runway timeline [3][4] - BBI-940, a novel Kinesin degrader targeting ecDNA segregation, is on track for investigational new drug submission, with a first-in-human clinical trial anticipated to start in the first half of 2026 [1][5]

Core Insights - Boundless Bio is a clinical-stage oncology company focused on developing therapies for oncogene amplified cancers through the study of extrachromosomal DNA (ecDNA) [2] Group 1: Company Overview - Boundless Bio is dedicated to addressing the unmet needs of patients with oncogene amplified tumors, which are linked to ecDNA observed in 14% to 17% of cancer patients [2] - The company is developing ecDNA-directed therapeutic candidates, including BBI-355, a selective CHK1 inhibitor, and BBI-825, a selective RNR inhibitor [2] - Boundless Bio is conducting a phase 1/2 clinical trial named POTENTIATE to evaluate the combination of BBI-355 and BBI-825 in patients with oncogene amplified cancers [2] Group 2: Upcoming Presentation - Boundless Bio will present a poster at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics from October 22-26, 2025, in Boston, MA [1] - The presentation will focus on the synergistic oral combination of BBI-825 and BBI-355 targeting unique dependencies of oncogene amplified cancers [1] - The poster session is scheduled for October 23, 2025, from 12:30 PM to 4:00 PM ET, located at Level 2, Exhibit Hall D [1]

Core Concept - Bloomingdale's is launching a transformative campaign titled "Just Imagine," which aims to redefine the retail experience by merging art, fashion, and immersive storytelling at its flagship store on 59th Street this fall [1][9]. Campaign Overview - The campaign features a façade installation and Carousel takeover by artist Yinka Ilori, who draws inspiration from the resilience and creativity of New York City [2][3]. - Ilori's design, titled "Cherish Your Magic," will include vibrant installations and product displays that reflect the dynamic spirit of the city [4][9]. Exclusive Collections - The campaign will showcase exclusive collections from Yinka Ilori and illustrator Angelica Hicks, including limited-edition items across various categories such as apparel, jewelry, and home décor [5][10]. - Retail prices for the limited-edition collection range from $16 for smaller items to $1,600 for high-end seating [8]. Interactive Experiences - Bloomingdale's will host a series of events and activities over two months, starting September 4, to engage customers in creative experiences [5][13]. - The flagship store will feature the Happy Medium Café, offering art experiences and hands-on activities for visitors [12]. Collaborations and Installations - The campaign includes collaborations with brands like PlayStation, which will feature a unique fusion of art and gaming [7]. - Various installations and interactive experiences will be available throughout the store, including custom pet portraits and live cooking demonstrations [13][18]. Duration and Locations - "Just Imagine" will run from September through October 2025, primarily at Bloomingdale's 59th Street location, with select elements available in other stores and online [14].

Core Viewpoint - Pringles is launching a new lineup of flavors, including the Smoky collection, Sharp White Cheddar, and Pringles Mingles flavors, aimed at satisfying diverse consumer cravings starting in September 2025 [2][5][8]. Product Launch Details - The new Pringles Smoky collection includes three flavors: Smoky Bacon, Smoky Mesquite BBQ, and Smoky Cheddar, each offering unique taste profiles [6][5]. - Pringles Sharp White Cheddar combines rich, nutty flavors with a touch of acidity to replicate aged white cheddar cheese [6]. - Pringles Mingles introduces two new flavors: Cinnamon & Sugar, which is the brand's first sweet flavor since 2016, and Jalapeño & Queso, balancing creamy queso with fresh jalapeño flavor [6][5]. Marketing and Collaboration - To celebrate the launch, Pringles is collaborating with Chef Calvin Eng from Bonnie's restaurant to create a special dish featuring the Smoky Mesquite BBQ flavor, available for a limited time [5][7]. - The marketing strategy emphasizes innovation and consumer engagement, with a focus on unique flavor experiences [4][8]. Company Background - Kellanova, the parent company of Pringles, is a leader in global snacking with a legacy of over 100 years and net sales of approximately $13 billion for 2024 [9].

Core Insights - Boundless Bio, a biotechnology company focused on targeted cancer therapies utilizing extrachromosomal DNA (ecDNA) biology, reported no revenue for Q2 2025, consistent with expectations for a pre-commercial biotech [1][2] - The company achieved a significant reduction in research and development expenses and made progress in its pipeline programs, with management confirming that its cash reserves of $127.1 million will fund operations into the first half of 2028 [1][6] Financial Performance - EPS (GAAP) for Q2 2025 was $(0.70), an improvement from $(0.77) in Q2 2024, reflecting a 9.1% year-over-year change [2] - Research and Development Expense decreased to $12.2 million from $14.7 million in Q2 2024, marking a 17.0% reduction [2][5] - General and Administrative Expense slightly increased to $4.8 million from $4.7 million in the same period last year [2][5] - The net loss for Q2 2025 was $15.7 million, down from $17.0 million in Q2 2024, indicating a 7.6% improvement [2][6] Pipeline and Clinical Developments - Boundless Bio's primary focus is on its Spyglass platform, which identifies drug targets related to ecDNA function, with its lead program BBI-355 targeting oncogene amplification [3][4] - The POTENTIATE trial for BBI-355 was expanded to test its efficacy both alone and in combination with BBI-825, with early preclinical data suggesting enhanced anticancer activity [7] - BBI-940 was nominated as a new development candidate, targeting kinesin, with plans to submit an Investigational New Drug application in the first half of 2026 [8] Future Outlook - Management did not provide formal financial guidance but reiterated that the current cash position supports operations through the first half of 2028, covering critical clinical milestones [9][10] - Investors should monitor the progress of the BBI-355/BBI-825 combination trial and the regulatory submission timeline for BBI-940, as success in these areas will be pivotal for future updates and funding needs [11]

[Special Note Regarding Forward-Looking Statements and Market and Industry Data](index=4&type=section&id=SPECIAL%20NOTE%20REGARDING%20FORWARD-LOOKING%20STATEMENTS%20AND%20MARKET%20AND%20INDUSTRY%20DATA) [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) This section outlines forward-looking statements, detailing risks such as limited operating history, capital needs, and unproven therapeutic approaches - The report contains forward-looking statements concerning future operations, financial position, use of IPO proceeds, cash runway, benefits of portfolio prioritization, timing and success of clinical trials, regulatory submissions, potential benefits of ecDTx, and intellectual property strategies[7](index=7&type=chunk) - Key risks include a limited operating history, significant operating losses, substantial additional capital requirements, early development stage with only one active clinical trial (BBI-355 and BBI-825 combination), novel and unproven approach to treating cancer with ecDTx, lengthy and expensive clinical development with uncertain outcomes, potential side effects, reliance on third parties, significant competition, and volatile stock price[8](index=8&type=chunk)[11](index=11&type=chunk) - The company operates in an evolving environment, and new risk factors and uncertainties may emerge, making forward-looking statements inherently subject to risks and uncertainties[9](index=9&type=chunk) [PART I. FINANCIAL INFORMATION](index=8&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements (Unaudited)](index=8&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) This section presents unaudited condensed financial statements, detailing financial position, operational performance, and cash flows [Condensed Balance Sheets](index=8&type=section&id=Condensed%20Balance%20Sheets) This section presents the company's financial position, detailing assets, liabilities, and stockholders' equity at specific dates | Metric (in thousands) | June 30, 2025 | December 31, 2024 | | :-------------------- | :------------ | :---------------- | | Total assets | $179,453 | $206,409 | | Total liabilities | $56,762 | $55,767 | | Total stockholders' equity | $122,691 | $150,642 | - Total assets decreased by **$26.96 million** from December 31, 2024, to June 30, 2025, primarily due to a reduction in cash, cash equivalents, and short-term investments[15](index=15&type=chunk) - Total stockholders' equity decreased by **$27.95 million**, largely driven by the accumulated deficit from net losses[15](index=15&type=chunk) [Condensed Statements of Operations and Comprehensive Loss](index=9&type=section&id=Condensed%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) This section details the company's operational performance, including revenues, expenses, and net loss over specific periods | Metric (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research and development | $12,218 | $14,735 | $24,355 | $27,864 | | General and administrative | $4,843 | $4,656 | $10,047 | $8,410 | | Total operating expenses | $17,061 | $19,391 | $34,402 | $36,274 | | Net loss | $(15,675) | $(16,976) | $(31,433) | $(32,406) | | Net loss per share, basic and diluted | $(0.70) | $(0.77) | $(1.41) | $(2.78) | - Net loss decreased by **$1.3 million** for the three months ended June 30, 2025, and by **$0.97 million** for the six months ended June 30, 2025, compared to the respective prior year periods[18](index=18&type=chunk) - Research and development expenses decreased by **$2.5 million** (3 months YoY) and **$3.5 million** (6 months YoY), while general and administrative expenses increased by **$0.2 million** (3 months YoY) and **$1.6 million** (6 months YoY)[18](index=18&type=chunk) [Condensed Statements of Convertible Preferred Stock and Stockholders' Equity/ (Deficit)](index=10&type=section&id=Condensed%20Statements%20of%20Convertible%20Preferred%20Stock%20and%20Stockholders'%20Equity/%20(Deficit)) This section outlines changes in convertible preferred stock and stockholders' equity, reflecting capital structure evolution and accumulated deficit | Metric (in thousands) | December 31, 2024 | March 31, 2025 | June 30, 2025 | | :-------------------- | :---------------- | :------------- | :------------ | | Total stockholders' equity | $150,642 | $136,592 | $122,691 | | Accumulated deficit | $(201,472) | $(217,230) | $(232,905) | - The accumulated deficit increased from **$(201.5) million** at December 31, 2024, to **$(232.9) million** at June 30, 2025, reflecting ongoing net losses[21](index=21&type=chunk) - Stock-based compensation contributed **$3.49 million** to additional paid-in capital during the six months ended June 30, 2025[21](index=21&type=chunk) [Condensed Statements of Cash Flows](index=11&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) This section details cash inflows and outflows from operating, investing, and financing activities over specific periods | Metric (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------- | :----------------------------- | :----------------------------- | | Net cash used in operating activities | $(26,359) | $(32,012) | | Net cash provided by/ (used in) investing activities | $14,352 | $(50,054) | | Net cash provided by financing activities | $117 | $89,723 | | Net increase/ (decrease) in cash, cash equivalents, and restricted cash | $(11,890) | $7,657 | - Net cash used in operating activities decreased by **$5.65 million** for the six months ended June 30, 2025, compared to the prior year, primarily due to reduced third-party spending on discovery, development, and clinical activities[24](index=24&type=chunk)[131](index=131&type=chunk) - Investing activities shifted from a net outflow of **$50.1 million** in H1 2024 to a net inflow of **$14.4 million** in H1 2025, driven by net maturities of available-for-sale securities[24](index=24&type=chunk)[132](index=132&type=chunk) - Financing activities provided significantly less cash in H1 2025 (**$0.1 million**) compared to H1 2024 (**$89.7 million**), as the prior period included net proceeds from the IPO[24](index=24&type=chunk)[133](index=133&type=chunk) [Notes to Condensed Financial Statements](index=12&type=section&id=Notes%20to%20Condensed%20Financial%20Statements) [1. Organization and Basis of Presentation](index=12&type=section&id=1.%20Organization%20and%20Basis%20of%20Presentation) This section describes the company's business, IPO details, and financial position, including cash runway and accumulated deficit - Boundless Bio, Inc is a clinical-stage precision oncology company focused on developing ecDNA-directed therapeutic candidates (ecDTx) for oncogene amplified tumors[27](index=27&type=chunk) - The company completed its IPO on April 2, 2024, selling 6,250,000 shares at $16.00 per share, generating approximately **$87.7 million** in net proceeds[28](index=28&type=chunk) - As of June 30, 2025, the company had **$127.1 million** in cash, cash equivalents, and short-term investments, which it believes will fund operations for at least twelve months[32](index=32&type=chunk)[36](index=36&type=chunk] It has an accumulated deficit of **$232.9 million** and expects to incur significant operating losses for the foreseeable future[32](index=32&type=chunk)[36](index=36&type=chunk) [2. Summary of Significant Accounting Policies](index=14&type=section&id=2.%20Summary%20of%20Significant%20Accounting%20Policies) This section outlines the accounting principles used in financial statement preparation, noting no material policy changes - The condensed financial statements are prepared in accordance with U.S GAAP and SEC interim reporting requirements, with certain footnote disclosures condensed or omitted[37](index=37&type=chunk) - There were no material changes to the company's significant accounting policies during the six months ended June 30, 2025[39](index=39&type=chunk) - The company qualifies as an 'emerging growth company' (EGC) and has elected to use the extended transition period for complying with new or revised financial accounting standards[40](index=40&type=chunk) [3. Fair Value Measurements](index=16&type=section&id=3.%20Fair%20Value%20Measurements) This section details the fair value of financial assets, categorizing them by valuation inputs (Level 1 and Level 2) | Asset Type (in thousands) | June 30, 2025 Fair Value | December 31, 2024 Fair Value | | :------------------------ | :----------------------- | :--------------------------- | | Money market funds (Level 1) | $11,797 | $24,889 | | U.S. government obligations (Level 2) | $112,451 | $118,289 | | Corporate debt securities (Level 2) | — | $7,238 | | Total fair value of assets | $124,248 | $150,416 | - Money market funds are classified as Level 1, while U.S government obligations and corporate debt securities are classified as Level 2, reflecting valuation based on observable market data[47](index=47&type=chunk) [4. Investments](index=16&type=section&id=4.%20Investments) This section provides details on the company's investment portfolio, including money market funds and government obligations | Investment Type (in thousands) | June 30, 2025 Estimated Fair Value | December 31, 2024 Estimated Fair Value | | :----------------------------- | :--------------------------------- | :----------------------------------- | | Money market funds | $11,797 | $24,889 | | U.S. government obligations | $112,451 | $118,289 | | Corporate debt securities | — | $7,238 | | Total cash equivalents and investments | $124,248 | $150,416 | - As of June 30, 2025, there were 21 available-for-sale securities with an estimated fair value of **$78.6 million** in gross unrealized loss positions, primarily due to the rising interest rate environment[52](index=52&type=chunk) [5. Property and Equipment](index=18&type=section&id=5.%20Property%20and%20Equipment) This section details the company's property and equipment, net of accumulated depreciation and amortization | Category (in thousands) | June 30, 2025 | December 31, 2024 | | :---------------------- | :------------ | :---------------- | | Lab equipment | $4,374 | $4,338 | | Computers and software | $899 | $895 | | Leasehold improvements | $1,030 | $981 | | Furniture and fixtures | $1,834 | $1,816 | | Total property and equipment | $8,137 | $8,030 | | Less accumulated depreciation and amortization | $(4,343) | $(3,709) | | Property and equipment, net | $3,794 | $4,321 | - Net property and equipment decreased from **$4.32 million** at December 31, 2024, to **$3.79 million** at June 30, 2025, primarily due to accumulated depreciation and amortization[53](index=53&type=chunk) [6. Accounts Payable and Accrued Liabilities](index=18&type=section&id=6.%20Accounts%20Payable%20and%20Accrued%20Liabilities) This section outlines the company's short-term liabilities, including accounts payable and accrued research and development costs | Category (in thousands) | June 30, 2025 | December 31, 2024 | | :---------------------- | :------------ | :---------------- | | Accounts payable | $2,294 | $1,274 | | Accrued research and development costs | $3,058 | $2,584 | | Other accrued liabilities | $503 | $1,496 | | Total accounts payable and accrued liabilities | $5,855 | $5,354 | - Total accounts payable and accrued liabilities increased by **$0.5 million** from December 31, 2024, to June 30, 2025, mainly driven by an increase in accounts payable and accrued R&D costs[54](index=54&type=chunk) [7. Lease Agreements](index=18&type=section&id=7.%20Lease%20Agreements) This section details the company's non-cancelable facility lease, including future minimum payments and operating lease liabilities - The company entered into a non-cancelable facility lease (2024 Lease) for its San Diego headquarters, commencing November 2024 with base rent payments starting July 2025, for a 120-month term[55](index=55&type=chunk)[57](index=57&type=chunk) - Future minimum lease payments under the 2024 Lease as of June 30, 2025, total **$72.3 million**, with operating lease liabilities recorded at **$49.5 million**[60](index=60&type=chunk) - Lease expense for the three months ended June 30, 2025, was approximately **$2.4 million**, significantly higher than **$0.7 million** in the prior year, due to the new 2024 Lease[58](index=58&type=chunk) [8. Commitments and Contingencies](index=20&type=section&id=8.%20Commitments%20and%20Contingencies) This section describes the company's contractual commitments, indemnification obligations, and absence of material litigation - The company enters into cancellable contracts for preclinical research, clinical trials, manufacturing, and other services, which generally provide for termination upon notice without significant penalty[61](index=61&type=chunk) - The company provides indemnification to vendors, lessors, business partners, officers, and directors, with potential future payments being unlimited in many cases, but no material costs have been incurred to date[62](index=62&type=chunk)[64](index=64&type=chunk) - There are no material outstanding litigation matters, and no liabilities for loss contingencies have been accrued as of June 30, 2025, or December 31, 2024[65](index=65&type=chunk) [9. Common Stock](index=22&type=section&id=9.%20Common%20Stock) This section details common stock options, equity awards, and shares available for issuance under employee plans | Category (in thousands) | June 30, 2025 | December 31, 2024 | | :---------------------- | :------------ | :---------------- | | Common stock options issued and outstanding | 4,647 | 3,818 | | Equity awards available for future issuance | 2,934 | 2,648 | | Shares available for purchase under employee stock purchase plan | 325 | 187 | | Total | 7,906 | 6,653 | - The total number of common stock shares reserved for future issuance increased from **6.65 million** at December 31, 2024, to **7.91 million** at June 30, 2025[66](index=66&type=chunk) [10. Stock-Based Compensation](index=22&type=section&id=10.%20Stock-Based%20Compensation) This section outlines the company's stock-based compensation plans, including options, exercise prices, and related expenses - The 2024 Incentive Award Plan became effective with the IPO, authorizing 3,765,892 shares for issuance as of June 30, 2025, including an evergreen provision increase[67](index=67&type=chunk) | Metric (in thousands, except per share data) | June 30, 2025 | December 31, 2024 | | :------------------------------------------- | :------------ | :---------------- | | Balance of stock options outstanding | 4,647 | 3,818 | | Weighted-average exercise price | $5.10 | $6.37 | | Unrecognized compensation cost (stock options) | $11,800 | N/A | | Unrecognized compensation cost (ESPP) | $700 | N/A | | Stock-Based Compensation Expense (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :---------------------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research and development | $642 | $888 | $1,357 | $1,412 | | General and administrative | $1,051 | $1,247 | $2,133 | $2,051 | | Total stock-based compensation | $1,693 | $2,135 | $3,490 | $3,463 | [11. Net Loss Per Common Share](index=24&type=section&id=11.%20Net%20Loss%20Per%20Common%20Share) This section presents the calculation of net loss per common share, basic and diluted, for the reported periods | Metric (in thousands, except per share data) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :------------------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net loss | $(15,675) | $(16,976) | $(31,433) | $(32,406) | | Weighted-average shares | 22,356 | 22,023 | 22,328 | 11,641 | | Net loss per share, basic and diluted | $(0.70) | $(0.77) | $(1.41) | $(2.78) | - Potential common shares from options were excluded from diluted net loss per share calculation as their inclusion would be anti-dilutive due to the net loss[79](index=79&type=chunk) [12. Segment Information](index=25&type=section&id=12.%20Segment%20Information) This section confirms the company operates as a single reporting segment, focusing on ecDTx development with no revenue | Expense Category (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :------------------------------ | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | R&D – Compensation and benefits | $3,217 | $3,679 | $6,512 | $7,165 | | R&D – Clinical trial costs | $2,448 | $2,935 | $5,298 | $5,532 | | G&A – Compensation and benefits | $1,528 | $1,645 | $3,102 | $3,192 | | Facilities related | $2,400 | $652 | $4,699 | $1,304 | | Total operating expense | $17,061 | $19,391 | $34,402 | $36,274 | - The company operates and manages its business as one reporting and one operating segment, focused on designing and developing ecDTx, with no revenue recorded to date[41](index=41&type=chunk)[81](index=81&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=26&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial condition and results, focusing on ecDNA therapeutics, portfolio prioritization, and financial impacts, including liquidity [Overview](index=26&type=section&id=Overview) This section provides an overview of the company's clinical-stage oncology focus, portfolio prioritization, and workforce reduction - Boundless Bio is a clinical-stage precision oncology company developing ecDNA-directed therapeutic candidates (ecDTx) for oncogene amplified tumors, a condition affecting **14% to 17%** of cancer patients[84](index=84&type=chunk) - The company announced a portfolio prioritization on May 23, 2025, focusing on the BBI-355/BBI-825 combination, advancing the Kinesin program with BBI-940, and extending its cash runway into the first half of 2028[86](index=86&type=chunk)[95](index=95&type=chunk) - Due to a narrow therapeutic index and lack of dose-proportional exposure, respectively, BBI-355 and BBI-825 single-agent clinical development arms were discontinued, but a combination arm for BBI-355/BBI-825 has been opened based on preclinical synergistic activity[87](index=87&type=chunk)[88](index=88&type=chunk)[89](index=89&type=chunk) - The company incurred a **$1.0 million** charge related to a workforce reduction of approximately one-third, completed by June 30, 2025, as part of streamlining operations[95](index=95&type=chunk) [Macroeconomic, Political, and Regulatory Environment Considerations](index=30&type=section&id=Macroeconomic,%20Political,%20and%20Regulatory%20Environment%20Considerations) This section addresses risks from macroeconomic, political, and regulatory environments, including market volatility and potential FDA delays - Uncertainty in global macroeconomic, political, and regulatory environments poses significant risks, including market volatility, high interest rates, inflation, and potential disruptions to service providers and clinical sites[99](index=99&type=chunk) - Changes at the FDA, such as staff departures or funding shortages, could delay regulatory approvals and increase development costs[100](index=100&type=chunk) [Components of Our Results of Operations](index=30&type=section&id=Components%20of%20Our%20Results%20of%20Operations) This section details the components of operating results, including R&D and G&A expenses, and future revenue expectations - The company has not generated any revenue from product sales to date and does not expect to until ecDTx achieve regulatory approval, which may take several years[102](index=102&type=chunk) - Operating expenses consist of research and development (R&D) and general and administrative (G&A) expenses[103](index=103&type=chunk) R&D expenses are primarily for the Spyglass platform, ecDTx discovery, preclinical/clinical development, and ecDNA diagnostic development[104](index=104&type=chunk) - G&A expenses include personnel costs, facility-related costs, legal fees, professional fees, and insurance[111](index=111&type=chunk) Both R&D and G&A expenses are expected to increase as the business grows and potentially commercializes products[112](index=112&type=chunk) [Results of Operations](index=34&type=section&id=Results%20of%20Operations) [Comparison of the Three Months Ended June 30, 2025 and 2024](index=34&type=section&id=Comparison%20of%20the%20Three%20Months%20Ended%20June%2030,%202025%20and%202024) This section compares financial performance for the three months ended June 30, 2025 and 2024, highlighting changes in expenses and net loss | Metric (in thousands) | June 30, 2025 | June 30, 2024 | Change | | :-------------------- | :------------ | :------------ | :----- | | Research and development | $12,218 | $14,735 | $(2,517) | | General and administrative | $4,843 | $4,656 | $187 | | Interest income | $1,386 | $2,382 | $(996) | | Net loss | $(15,675) | $(16,976) | $1,301 | - R&D expenses decreased by **$2.5 million**, primarily due to reduced spending on the BBI-825 clinical trial and lower personnel, outside services, and lab supply costs, partially offset by increased facilities-related expenses[116](index=116&type=chunk) - G&A expenses increased by **$0.2 million**, mainly due to higher facilities-related costs, partially offset by decreased stock-based compensation and other personnel costs[117](index=117&type=chunk) - Other income, net, decreased by **$1.0 million** due to a reduction in interest income from a smaller investment portfolio and lower market yields[118](index=118&type=chunk) [Comparison of the Six Months Ended June 30, 2025 and 2024](index=36&type=section&id=Comparison%20of%20the%20Six%20Months%20Ended%20June%2030,%202025%20and%202024) This section compares financial performance for the six months ended June 30, 2025 and 2024, highlighting changes in expenses and net loss | Metric (in thousands) | June 30, 2025 | June 30, 2024 | Change | | :-------------------- | :------------ | :------------ | :----- | | Research and development | $24,355 | $27,864 | $(3,509) | | General and administrative | $10,047 | $8,410 | $1,637 | | Interest income | $2,971 | $3,803 | $(832) | | Net loss | $(31,433) | $(32,406) | $973 | - R&D expenses decreased by **$3.5 million**, driven by reduced direct program costs for BBI-825, lower personnel, outside services, and lab supply costs, partially offset by a **$2.7 million** increase in facilities-related expenses[120](index=120&type=chunk) - G&A expenses increased by **$1.6 million**, primarily due to a **$1.0 million** increase in facilities-related costs and a **$0.5 million** increase in professional service fees[121](index=121&type=chunk) - Other income, net, decreased by **$0.9 million** due to reduced interest income from a smaller investment portfolio and lower market yields[122](index=122&type=chunk) [Liquidity and Capital Resources](index=37&type=section&id=Liquidity%20and%20Capital%20Resources) This section details the company's capital raised, current cash position, projected cash runway, and future funding requirements - The company has raised **$353.8 million** to date, primarily from convertible preferred stock and common stock sales, including **$87.7 million** net proceeds from its April 2024 IPO[123](index=123&type=chunk) - As of June 30, 2025, cash, cash equivalents, and short-term investments totaled **$127.1 million**, projected to fund operations into the first half of 2028[126](index=126&type=chunk) - The company expects to incur substantial losses for the foreseeable future and will require significant additional funding, likely through equity offerings, debt financings, or collaborations, to support its development and potential commercialization efforts[127](index=127&type=chunk)[129](index=129&type=chunk) | Cash Flow Activity (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------------------- | :----------------------------- | :----------------------------- | | Net cash used in operating activities | $(26,359) | $(32,012) | | Net cash provided by/ (used in) investing activities | $14,352 | $(50,054) | | Net cash provided by financing activities | $117 | $89,723 | [Contractual Obligations and Other Commitments](index=42&type=section&id=Contractual%20Obligations%20and%20Other%20Commitments) This section outlines the company's operating lease commitments and cancellable contracts for services - As of June 30, 2025, total future aggregate operating lease commitments for office and lab space amount to **$72.3 million**, expiring in October 2034[134](index=134&type=chunk) - The company enters into cancellable contracts for clinical trial, preclinical research, and manufacturing services, which are not separately presented as they generally allow for termination after a notice period[135](index=135&type=chunk) [Off-Balance Sheet Arrangements](index=42&type=section&id=Off-Balance%20Sheet%20Arrangements) This section confirms the absence of any off-balance sheet arrangements since the company's inception - The company has not had any off-balance sheet arrangements since its inception, as defined under SEC rules and regulations[136](index=136&type=chunk) [Critical Accounting Policies and Significant Estimates and Judgments](index=42&type=section&id=Critical%20Accounting%20Policies%20and%20Significant%20Estimates%20and%20Judgments) This section discusses key accounting policies and estimates, particularly for R&D expenses and stock-based compensation - The preparation of financial statements requires management to make estimates and judgments, particularly concerning accrued R&D expenses and stock-based compensation[137](index=137&type=chunk) - There have been no material changes to the company's critical accounting policies and estimates from those described in its 2024 10-K[138](index=138&type=chunk) [Emerging Growth Company and Smaller Reporting Company Status](index=42&type=section&id=Emerging%20Growth%20Company%20and%20Smaller%20Reporting%20Company%20Status) This section explains the company's status as an EGC and smaller reporting company, detailing associated disclosure elections - The company qualifies as an 'emerging growth company' (EGC) and has elected to use the extended transition period for complying with new or revised accounting standards, allowing delayed adoption[139](index=139&type=chunk) - The company will remain an EGC until the earliest of December 31, 2029, or other conditions related to revenue, market value, or debt issuance[140](index=140&type=chunk) - The company is also a 'smaller reporting company' and can take advantage of scaled disclosures as long as its public float or annual revenue remains below specified thresholds[141](index=141&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=44&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, Boundless Bio, Inc is not required to provide quantitative and qualitative disclosures about market risk - The company is a smaller reporting company and is not required to provide quantitative and qualitative disclosures about market risk[143](index=143&type=chunk) [Item 4. Controls and Procedures](index=44&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls were effective as of June 30, 2025, with internal control over financial reporting evaluation deferred for newly public companies - As of June 30, 2025, the company's disclosure controls and procedures were effective in providing reasonable assurance that required information is recorded, processed, summarized, and reported timely[144](index=144&type=chunk) - Due to SEC rules for newly public companies, management is not yet required to evaluate the effectiveness of internal control over financial reporting until after the filing of the 2025 Annual Report on Form 10-K[145](index=145&type=chunk) [PART II. OTHER INFORMATION](index=45&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=45&type=section&id=Item%201.%20Legal%20Proceedings) There are no material pending legal proceedings against the company, nor is management aware of any contemplated governmental proceedings - There are no material pending legal proceedings against the company, and management is unaware of any contemplated governmental proceedings[148](index=148&type=chunk) [Item 1A. Risk Factors](index=45&type=section&id=Item%201A.%20Risk%20Factors) Investing in the company's common stock involves high risk, with no material changes to previously disclosed risk factors in the 2024 10-K - Investing in the company's common stock involves a high degree of risk, and investors should carefully consider the risks and uncertainties described in the 2024 10-K[149](index=149&type=chunk) - There have been no material changes to the risk factors set forth in Part I, Item 1A of the company's 2024 10-K[149](index=149&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=45&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section reports no unregistered sales or issuer purchases, detailing the shifted use of IPO proceeds to support BBI-355/BBI-825 and BBI-940 programs [(a) Recent Sales of Unregistered Securities.](index=45&type=section&id=(a)%20Recent%20Sales%20of%20Unregistered%20Securities.) This section confirms there have been no recent unregistered sales of equity securities by the company - There have been no recent unregistered sales of equity securities[150](index=150&type=chunk) [(b) Use of Proceeds.](index=45&type=section&id=(b)%20Use%20of%20Proceeds.) This section details the net proceeds from the April 2024 IPO and their reallocated use for key therapeutic programs - The IPO, completed on April 2, 2024, generated net proceeds of approximately **$87.7 million** after deducting underwriting discounts and offering expenses[151](index=151&type=chunk) - The planned use of IPO net proceeds has shifted due to portfolio prioritization, now directed to support the BBI-355/BBI-825 combination and BBI-940 programs, including initial proof-of-concept clinical data, research and development of other ecDTx programs, and general corporate purposes[152](index=152&type=chunk) [(c) Issuer Purchases of Equity Securities.](index=45&type=section&id=(c)%20Issuer%20Purchases%20of%20Equity%20Securities.) This section confirms there have been no issuer purchases of equity securities by the company - There have been no issuer purchases of equity securities[153](index=153&type=chunk) [Item 3. Defaults Upon Senior Securities](index=45&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) Boundless Bio, Inc has not defaulted upon any senior securities - There have been no defaults upon senior securities[154](index=154&type=chunk) [Item 4. Mine Safety Disclosures](index=47&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to Boundless Bio, Inc - This item is not applicable[155](index=155&type=chunk) [Item 5. Other Information](index=47&type=section&id=Item%205.%20Other%20Information) This section discloses a Rule 10b5-1 trading arrangement adopted by the Chief Medical Officer for 45,000 shares - Robert Doebele, MD, Ph.D, Chief Medical Officer, adopted a Rule 10b5-1 trading arrangement on April 3, 2025, covering **45,000 shares** with an expiration date of August 3, 2026[156](index=156&type=chunk)[157](index=157&type=chunk) [Item 6. Exhibits](index=48&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with Form 10-Q, including corporate governance documents and officer certifications - The exhibits include the Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws, certifications of principal executive and financial officers (31.1, 31.2, 32.1), and Inline XBRL documents (101.INS, 101.SCH, 104)[160](index=160&type=chunk)

[Executive Summary & Business Highlights](index=1&type=section&id=Executive%20Summary%20%26%20Business%20Highlights) Boundless Bio initiated enrollment for its BBI-355/BBI-825 combination trial and advanced BBI-940 towards IND submission, with **$127 million** cash funding operations into H1 2028 [Key Announcements](index=1&type=section&id=Key%20Announcements) Boundless Bio opened enrollment for the BBI-355/BBI-825 combination trial and confirmed BBI-940's IND submission timeline, supported by a **$127 million** cash runway - BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment[2](index=2&type=chunk) - BBI-940 is on track for submission of an investigational new drug (IND) application in the first half of 2026[2](index=2&type=chunk) - **$127 million** in cash supports operations into the first half of 2028, through expected proof-of-concept clinical readouts for both programs[2](index=2&type=chunk) [CEO Commentary](index=1&type=section&id=CEO%20Commentary) CEO Zachary Hornby emphasized focused execution on programs with strong scientific rationale and significant potential for patients with oncogene-amplified cancers - Company is executing with sharpened focus on programs believed to have the strongest scientific rationale and greatest potential to impact patients with oncogene-amplified cancers[3](index=3&type=chunk) - Excited to advance BBI-355/BBI-825 combination in the clinic and progress BBI-940 toward IND submission[3](index=3&type=chunk) [Research and Development Highlights and Upcoming Milestones](index=1&type=section&id=Research%20and%20Development%20Highlights%20and%20Upcoming%20Milestones) Boundless Bio is advancing its POTENTIATE clinical trial with a BBI-355/BBI-825 combination and progressing BBI-940 towards an IND submission, with initial clinical data expected within the current cash runway [POTENTIATE Clinical Trial](index=1&type=section&id=POTENTIATE%20clinical%20trial) Preclinical data supports the BBI-355/BBI-825 combination for synergistic anti-tumor activity, with the POTENTIATE trial's combination arm now open for enrollment and initial data expected within the cash runway - Preclinical data provides strong mechanistic rationale to combine BBI-355 (CHK1 inhibitor) with BBI-825 (RNR inhibitor) for synergistic anti-tumor activity without overlapping toxicity[5](index=5&type=chunk) - The BBI-355/BBI-825 combination arm of the POTENTIATE trial is open for enrollment[5](index=5&type=chunk) - Initial proof-of-concept clinical data for the combination is expected within the existing cash runway timeline[5](index=5&type=chunk) [Novel Kinesin Program](index=1&type=section&id=Novel%20Kinesin%20program%20targeting%20ecDNA%20segregation%20and%20inheritance) Boundless Bio selected BBI-940 as its development candidate for a novel kinesin program, with an IND submission planned for H1 2026 and initial clinical data expected within the current cash runway - Boundless selected BBI-940 as its development candidate for its novel program targeting a previously undrugged kinesin[5](index=5&type=chunk) - Boundless expects to submit an IND application for BBI-940 in the first half of 2026[5](index=5&type=chunk) - Initial proof-of-concept clinical data for BBI-940 is expected within the existing cash runway timeline[5](index=5&type=chunk) [Second Quarter 2025 Financial Results](index=2&type=section&id=Second%20Quarter%202025%20Financial%20Results) Boundless Bio reported a **$127.1 million** cash position, with a reduced net loss of **$15.7 million** for Q2 2025, driven by decreased R&D expenses [Summary of Financial Performance](index=2&type=section&id=Summary%20of%20Financial%20Performance) Boundless Bio's cash position of **$127.1 million** as of June 30, 2025, is projected to fund operations into H1 2028, with Q2 2025 net loss improving to **$15.7 million** - Cash, cash equivalents, and short-term investments totaled **$127.1 million** as of June 30, 2025, supporting operations into the first half of 2028[2](index=2&type=chunk)[10](index=10&type=chunk) Q2 2025 vs Q2 2024 Operating Expenses and Net Loss Highlights | Metric | Q2 2025 (Millions USD) | Q2 2024 (Millions USD) | Change (YoY) | | :-------------------------------- | :--------------------- | :--------------------- | :----------- | | Research and Development (R&D) Expenses | $12.2 | $14.7 | -$2.5 (-17.0%) | | General and Administrative (G&A) Expenses | $4.8 | $4.7 | +$0.1 (+2.1%) | | Net Loss | $15.7 | $17.0 | -$1.3 (-7.6%) | [Condensed Statements of Operations](index=4&type=section&id=Condensed%20Statements%20of%20Operations%20Data) Q2 2025 saw a **12.0%** decrease in total operating expenses and a **7.7%** improvement in net loss, while H1 2025 net loss per share significantly improved due to increased weighted-average shares Condensed Statements of Operations Data (Three Months Ended June 30) | Metric (in thousands USD) | Q2 2025 | Q2 2024 | Change (YoY) | | :-------------------- | :------ | :------ | :----------- | | Research and development | $12,218 | $14,735 | -$2,517 (-17.1%) | | General and administrative | $4,843 | $4,656 | +$187 (+4.0%) | | Total operating expenses | $17,061 | $19,391 | -$2,330 (-12.0%) | | Loss from operations | $(17,061) | $(19,391) | +$2,330 (+12.0%) | | Interest income | $1,386 | $2,382 | -$996 (-41.8%) | | Net loss | $(15,675) | $(16,976) | +$1,301 (+7.7%) | | Net loss per share, basic and diluted | $(0.70) | $(0.77) | +$0.07 (+9.1%) | | Weighted-average shares used in calculation | 22,356 | 22,023 | +333 (+1.5%) | Condensed Statements of Operations Data (Six Months Ended June 30) | Metric (in thousands USD) | H1 2025 | H1 2024 | Change (YoY) | | :-------------------- | :------ | :------ | :----------- | | Research and development | $24,355 | $27,864 | -$3,509 (-12.6%) | | General and administrative | $10,047 | $8,410 | +$1,637 (+19.5%) | | Total operating expenses | $34,402 | $36,274 | -$1,872 (-5.2%) | | Loss from operations | $(34,402) | $(36,274) | +$1,872 (+5.2%) | | Interest income | $2,971 | $3,803 | -$832 (-21.9%) | | Net loss | $(31,433) | $(32,406) | +$973 (+3.0%) | | Net loss per share, basic and diluted | $(1.41) | $(2.78) | +$1.37 (+49.3%) | | Weighted-average shares used in calculation | 22,328 | 11,641 | +10,687 (+91.8%) | [Condensed Balance Sheet](index=4&type=section&id=Condensed%20Balance%20Sheet%20Data) As of June 30, 2025, cash, cash equivalents, and short-term investments decreased by **$24.97 million**, contributing to a decline in total assets and stockholders' equity, while the accumulated deficit increased Condensed Balance Sheet Data (as of June 30, 2025 vs. December 31, 2024) | Metric (in thousands USD) | June 30, 2025 | December 31, 2024 | Change | | :-------------------------------- | :-------------- | :---------------- | :------- | | Cash, cash equivalents, and short-term investments | $127,148 | $152,114 | -$24,966 | | Total assets | $179,453 | $206,409 | -$26,956 | | Total liabilities | $56,762 | $55,767 | +$995 | | Accumulated deficit | $(232,905) | $(201,472) | -$31,433 | | Total stockholders' equity | $122,691 | $150,642 | -$27,951 | | Working capital | $120,477 | $146,255 | -$25,778 | [About Boundless Bio](index=2&type=section&id=About%20Boundless%20Bio) Boundless Bio is a clinical-stage oncology company developing ecDNA-directed therapies, including BBI-355 and BBI-825 in clinical trials, and BBI-940 in IND-enabling studies - Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics by addressing unmet needs in patients with oncogene amplified tumors, focusing on extrachromosomal DNA (ecDNA)[2](index=2&type=chunk)[7](index=7&type=chunk) - The company is developing the first ecDNA-directed therapeutic candidates (ecDTx), BBI-355 (oral, selective CHK1 inhibitor) and BBI-825 (oral, selective RNR inhibitor), evaluated in combination in the Phase 1/2 POTENTIATE clinical trial[7](index=7&type=chunk) - Boundless Bio is conducting IND-enabling studies for BBI-940, a potentially first-in-class orally bioavailable, selective Kinesin degrader[7](index=7&type=chunk) [Forward-Looking Statements](index=2&type=section&id=Forward-Looking%20Statements) This section cautions that non-historical statements are forward-looking, subject to inherent risks and uncertainties, and the company undertakes no obligation to update them, as qualified by safe harbor provisions - Statements not describing historical facts are forward-looking, identifiable by terms such as 'anticipate,' 'expect,' 'potential,' and are based on current beliefs and expectations[9](index=9&type=chunk) - Forward-looking statements are subject to inherent risks and uncertainties, including early development stage, novel and unproven approach, potential delays in clinical trials, dependence on third parties, and potential for unfavorable results or inadequate efficacy[9](index=9&type=chunk)[11](index=11&type=chunk) - The Company undertakes no obligation to update such statements, which are qualified in their entirety by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995[11](index=11&type=chunk) [Company Information](index=3&type=section&id=Company%20Information) This section provides essential contact information for investor relations and media inquiries [Investor and Media Contacts](index=3&type=section&id=Investor%20Contacts) Contact details are provided for investor relations, including James Lee and Renee Leck, and for media inquiries, Carly Scaduto - Investor Contacts: James Lee (Boundless Bio, Inc.) and Renee Leck (THRUST Strategic Communications)[12](index=12&type=chunk) - Media Contact: Carly Scaduto[12](index=12&type=chunk)